CMPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Checkmate Pharmaceuticals's enterprise value is $171.37 Mil. Checkmate Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-63.07 Mil. Therefore, Checkmate Pharmaceuticals's EV-to-EBITDA for today is -2.72.
The historical rank and industry rank for Checkmate Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest EV-to-EBITDA of Checkmate Pharmaceuticals was 891.56. The lowest was -1110.59. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-06), Checkmate Pharmaceuticals's stock price is $10.50. Checkmate Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.920. Therefore, Checkmate Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Checkmate Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkmate Pharmaceuticals Annual Data | |||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | |||||
EV-to-EBITDA | - | - | -5.95 | 0.14 |
Checkmate Pharmaceuticals Quarterly Data | ||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -4.08 | -0.81 | -0.08 | 0.14 | -0.14 |
For the Biotechnology subindustry, Checkmate Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Checkmate Pharmaceuticals's EV-to-EBITDA falls into.
Checkmate Pharmaceuticals's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 171.368 | / | -63.067 | |
= | -2.72 |
Checkmate Pharmaceuticals's current Enterprise Value is $171.37 Mil.
Checkmate Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkmate Pharmaceuticals (NAS:CMPI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Checkmate Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 10.50 | / | -2.920 | |
= | At Loss |
Checkmate Pharmaceuticals's share price for today is $10.50.
Checkmate Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Venbio Global Strategic Fund Ii L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Alan Bash | director, officer: Chief Executive Officer | C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Jon Marc Wigginton | director | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Joy Yan | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Arthur M Krieg | director, officer: Chief Scientific Officer | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Robert Dolski | officer: Chief Financial Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Barry Labinger | director, officer: President and CEO | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Peter Colabuono | director | C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025 |
Oren Isacoff | director | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Karen Brennan | officer: Chief Operating Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Kleem Chaudhary | officer: Chief Business Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Venbio Global Strategic Gp Ii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Gp Ii, Ltd. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Nilesh Kumar | director | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
From GuruFocus
By PRNewswire PRNewswire • 05-27-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By PRNewswire PRNewswire • 04-27-2022
By PRNewswire PRNewswire • 06-16-2022
By GuruFocus Research GuruFocus Editor • 08-16-2022
By Business Wire Business Wire • 05-17-2022
By PRNewswire PRNewswire • 06-15-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By GuruFocusNews GuruFocusNews • 05-22-2022
By PRNewswire PRNewswire • 05-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.